| Entry |
|
|---|
| Name |
Repaglinide (JAN/USP/INN);
Prandin (TN);
Surepost (TN)
|
|---|
| Product |
|
|---|
| Generic |
REPAGLINIDE (American Health Packaging), REPAGLINIDE (Aurobindo Pharma Limited), REPAGLINIDE (Breckenridge Pharmaceutical), PRANDIN (Gemini Laboratories), PRANDIN (Gemini Laboratories), REPAGLINIDE (Golden State Medical Supply), REPAGLINIDE (Mylan Institutional), REPAGLINIDE (Mylan Pharmaceuticals), REPAGLINIDE (Paddock Laboratories), REPAGLINIDE (Rising Health), REPAGLINIDE (Sandoz), REPAGLINIDE (Sun Pharmaceutical Industries) |
|---|
| Formula |
C27H36N2O4
|
|---|
| Exact mass |
452.2675
|
|---|
| Mol weight |
452.5857
|
|---|
| Structure |
   |
|---|
| Simcomp |
 |
|---|
| Class |
|
|---|
| Remark |
| Therapeutic category: | 3969 |
| Product (mixture): | D10500<US> |
|
|---|
| Efficacy |
Antidiabetic, Hypoglycemic, Sulfonylurea receptor agonist |
|---|
| Disease |
Type 2 diabetes mellitus [DS: H00409] |
|---|
| Comment |
Glinide derivative
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Metabolism |
Enzyme: CYP2C8 [HSA: 1558]; CYP3A4 [HSA: 1576]
|
|---|
| Interaction |
|
|---|
| Structure map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A10 DRUGS USED IN DIABETES
A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10BX Other blood glucose lowering drugs, excl. insulins
A10BX02 Repaglinide
D00594 Repaglinide (JAN/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Blood Glucose Regulators
Antidiabetic Agents
Repaglinide
D00594 Repaglinide (JAN/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
396 Antidiabetic agents
3969 Others
D00594 Repaglinide (JAN/USP/INN)
Target-based classification of drugs [BR:br08310]
Transporters
ABC transporters
ABCC subfamily
ABCC8(SUR1)/KCNJ11(KIR6.2)
D00594 Repaglinide (JAN/USP/INN) <JP/US>
Drug classes of therapeutic agents [br08360.html]
Antidiabetic agents
D00594
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D00594
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D00594
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D00594
 |
|---|
| Other DBs |
|
|---|
| LinkDB |
 |
|---|
| KCF data |
ATOM 33
1 C8y C 29.5484 -19.4440
2 C8y C 29.5543 -20.8486
3 N1y N 28.3361 -18.7446
4 C8x C 30.7608 -18.7446
5 C1c C 28.3478 -21.5481
6 C8x C 30.7608 -21.5423
7 C1x C 28.3361 -17.3457
8 C1x C 27.1296 -19.4497
9 C8x C 31.9790 -19.4440
10 N1b N 27.1296 -20.8486
11 C1b C 28.3478 -22.9469
12 C8x C 31.9790 -20.8486
13 C1x C 27.1238 -16.6520
14 C1x C 25.9114 -18.7503
15 C5a C 25.9173 -21.5481
16 C1c C 29.5543 -23.6521
17 C1x C 25.9114 -17.3514
18 C1b C 24.7049 -20.8486
19 O5a O 25.9173 -22.9469
20 C1a C 29.5543 -25.0569
21 C1a C 30.7666 -22.9469
22 C8y C 23.4867 -21.5481
23 C8x C 22.2744 -20.8486
24 C8x C 23.4867 -22.9469
25 C8y C 21.0679 -21.5538
26 C8x C 22.2744 -23.6521
27 C8y C 21.0562 -22.9469
28 O2a O 19.8556 -20.8603
29 C6a C 19.8497 -23.6521
30 C1b C 18.6432 -21.5538
31 O6a O 18.6375 -22.9410
32 O6a O 19.9140 -25.0510
33 C1a C 17.4309 -20.8603
BOND 35
1 1 2 1
2 1 3 1
3 1 4 2
4 2 5 1
5 2 6 2
6 3 7 1
7 3 8 1
8 4 9 1
9 5 10 1
10 5 11 1 #Down
11 6 12 1
12 7 13 1
13 8 14 1
14 10 15 1
15 11 16 1
16 13 17 1
17 15 18 1
18 15 19 2
19 16 20 1
20 16 21 1
21 18 22 1
22 22 23 2
23 22 24 1
24 23 25 1
25 24 26 2
26 25 27 2
27 25 28 1
28 27 29 1
29 28 30 1
30 29 31 1
31 29 32 2
32 30 33 1
33 9 12 2
34 14 17 1
35 26 27 1
|
|---|
